

Experimental Review on Chronic and Progressive Neurodegenerative Digestive Disease

Ahmed Zayed*

Department of Health and Life Sciences, Glasgow Caledonian University, UK

*Corresponding author: Ahmed Zayed, Department of Health and Life Sciences, Glasgow Caledonian University, UK, E-mail: zayed.987@gmail.com

Received date: May 26, 2023, Manuscript No. IPDD-23-17410; Editor assigned date: May 29, 2023, PreQC No. IPDD-23-17410 (PQ); Reviewed date: June 08, 2023, QC No. IPDD-23-17410; Revised date: June 14, 2023, Manuscript No. IPDD-23-17410 (R); Published date: June 20, 2023, DOI: 10.36648/2471-8521.9.2.53

Citation: Zayed A (2023) Experimental Review on Chronic and Progressive Neurodegenerative Digestive Disease. G J Dig Dis Vol.9 No.2:53.

Description

Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder that primarily affects the central nervous system. Named after the British physician James Parkinson, who first described the condition in his essay "An Essay on the Shaking Palsy" in 1817, it remains one of the most prevalent and debilitating neurodegenerative diseases worldwide. Over the years, extensive research has shed light on the underlying mechanisms, risk factors, symptoms, and potential treatments for this complex disorder. This article will delve into the various aspects of Parkinson's disease, exploring its etiology, clinical manifestations, current treatments, ongoing research, and the hope for a future cure. Parkinson's disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, a region of the brain responsible for producing dopamine - a crucial neurotransmitter involved in motor control and various other functions. The exact cause of this neurodegenerative process is not entirely understood, but both genetic and environmental factors are believed to play a role. Approximately 10-15% of PD cases are considered familial, suggesting a genetic component in the disease's etiology. Mutations in specific genes, such as SNCA, LRRK2, Parkin, PINK1, and DJ-1, have been linked to the development of Parkinson's disease. Understanding these genetic factors has not only provided insights into the pathogenesis but also paved the way for potential genetic therapies in the future. Several environmental factors have been associated with an increased risk of developing Parkinson's disease.

Neuroprotective Strategies

Exposure to certain toxins, such as pesticides and industrial chemicals, has been linked to a higher incidence of the disease. Additionally, head injuries and certain lifestyle factors, such as smoking and caffeine intake, have been suggested to influence PD risk. The hallmark symptoms of Parkinson's disease include motor impairments, such as bradykinesia (slowness of movement), resting tremors, rigidity, and postural instability. However, PD is a complex disorder that goes beyond motor symptoms. Patients may also experience non-motor symptoms, including cognitive impairment, depression, sleep disturbances, autonomic dysfunction, and sensory problems. The presentation and progression of Parkinson's disease can vary significantly

among individuals. Early stages may involve subtle motor changes and non-specific symptoms, making diagnosis challenging. As the disease advances, symptoms become more pronounced, affecting the individual's ability to perform daily activities and impacting their overall quality of life. Diagnosing Parkinson's disease is primarily based on clinical observation and medical history. Neurological examinations and assessment of motor symptoms play a crucial role in the diagnosis. Currently, there is no definitive test to confirm PD, leading to a reliance on experienced neurologists to make accurate diagnoses. In some cases, neuroimaging techniques, such as positron emission tomography (PET) and single-photon emission computerized tomography (SPECT), can be used to aid diagnosis and differentiate PD from other conditions with similar symptoms. Researchers continue to explore biomarkers that could facilitate early and accurate diagnosis, enabling early intervention and improved patient outcomes. While there is no cure for Parkinson's disease, several treatment strategies aim to manage symptoms and improve the patient's quality of life. Levodopa, a precursor of dopamine, is the most effective and commonly prescribed medication for managing PD symptoms. It helps replenish the brain's dopamine levels, alleviating motor symptoms. However, its long-term use can lead to motor fluctuations and dyskinesias. Other medications, such as dopamine agonists, MAO-B inhibitors, and COMT inhibitors, are also used alone or in combination with levodopa to manage symptoms and delay disease progression. Deep brain stimulation is a surgical procedure where electrodes are implanted into specific brain regions to deliver electrical impulses. DBS has shown significant success in managing motor symptoms, especially in patients with advanced PD and levodopa-related complications. However, it does not slow or halt disease progression. Physical therapy and occupational therapy play vital roles in helping PD patients maintain mobility, improve balance, and manage daily activities despite the disease's progressive nature. Speech therapy may also be recommended to address speech and swallowing difficulties. While current treatments provide symptomatic relief, they do not alter the underlying disease process. Consequently, there is an urgent need for disease-modifying therapies and ultimately a cure for Parkinson's disease. Researchers and scientists worldwide are actively engaged in various avenues of research to unravel the complexities of the disease and develop effective interventions. One promising area of research is the

development of neuroprotective therapies aimed at slowing or halting the degeneration of dopaminergic neurons. Various compounds, including antioxidants, anti-inflammatory agents, and growth factors, are being investigated for their potential neuroprotective effects. Advancements in gene therapy hold promise for treating Parkinson's disease, especially for individuals with specific genetic mutations associated with the condition.

Ongoing Research and Future Prospects

Gene editing techniques, such as CRISPR-Cas9, offer the potential to correct or replace defective genes, potentially halting the progression of the disease. Stem cell therapy is a cutting-edge approach that involves transplanting stem cells into the brain to replace lost or damaged dopaminergic neurons. While still in early stages of research, stem cell therapy shows

potential for restoring dopamine production and function, offering a potential cure for Parkinson's disease in the future. The concept of personalized medicine involves tailoring treatments to an individual's unique genetic and biological characteristics. Advancements in genetics and the development of biomarkers may enable the identification of subtypes of Parkinson's disease and guide more targeted and effective treatments. Parkinson's disease is a multifaceted and challenging neurodegenerative disorder that affects millions of people worldwide. While much progress has been made in understanding its etiology and managing its symptoms, the quest for a cure remains ongoing. Through continued research, advancements in genetics, stem cell therapies, and personalized medicine, there is hope for a future where Parkinson's disease becomes a treatable condition, and patients can enjoy a better quality of life without the burden of this debilitating disorder.